Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Trastornos del movimiento Movement disorders 321 artículos Viendo del 121 al 160 de 321 artículos
Pub MED

Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.NUEVO

Grünblatt E, Ruder J, Monoranu CM, Riederer P, Youdim MB, Mandel SA.
Neurotox Res. 2017 Dec 7. doi: 10.1007/s12640-017-9843-5. [Epub ahead of print]
Pub MED

Can a cognitive rehabilitation program in early stages of Parkinson's disease improve cognition, apathy and brain functional connectivity for up to 18 months?NUEVO

Daniele A, Panza F.
Eur J Neurol. 2017 Dec 7. doi: 10.1111/ene.13542. [Epub ahead of print] No abstract available.
Pub MED

A highly sensitive miR-195 nanobiosensor for early detection of Parkinson's disease.NUEVO

Aghili Z, Nasirizadeh N, Divsalar A, Shoeibi S, Yaghmaei P.
Artif Cells Nanomed Biotechnol. 2017 Dec 7:1-9. doi: 10.1080/21691401.2017.1411930. [Epub ahead of print]
Pub MED

Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson's and Alzheimer's Diseases.NUEVO

Boyko AA, Troyanova NI, Kovalenko EI, Sapozhnikov AM.
Int J Mol Sci. 2017 Dec 6;18(12). pii: E2633. doi: 10.3390/ijms18122633. Review.
Pub MED

Sleep quality is associated with the severity of clinical symptoms in Parkinson's disease.NUEVO

Junho BT, Kummer A, Cardoso FE, Teixeira AL, Rocha NP.
Acta Neurol Belg. 2017 Dec 5. doi: 10.1007/s13760-017-0868-6. [Epub ahead of print]
Pub MED

PBPK/PD assessment for Parkinson's disease risk posed by airborne pesticide paraquat exposure.NUEVO

Cheng YH, Chou WC, Yang YF, Huang CW, How CM, Chen SC, Chen WY, Hsieh NH, Lin YJ, You SH, Liao CM.
Environ Sci Pollut Res Int. 2017 Dec 5. doi: 10.1007/s11356-017-0875-4. [Epub ahead of print]
Pub MED

Association of variants in microRNA with Parkinson's disease in Chinese Han population.NUEVO

Li F, Liu H, Cheng Y, Yang J, Liu Y, Wang Y, Yang Z, Shi C, Xu Y.
Neurol Sci. 2017 Dec 5. doi: 10.1007/s10072-017-3210-4. [Epub ahead of print]
Pub MED

Sentence-Level Movements in Parkinson's Disease: Loud, Clear, and Slow Speech.NUEVO

Kearney E, Giles R, Haworth B, Faloutsos P, Baljko M, Yunusova Y.
J Speech Lang Hear Res. 2017 Dec 20;60(12):3426-3440. doi: 10.1044/2017_JSLHR-S-17-0075.
Pub MED

Positron emission tomography in Parkinson's disease: insights into impulsivity.NUEVO

Stark AJ, Claassen DO.
Int Rev Psychiatry. 2017 Dec;29(6):618-627. doi: 10.1080/09540261.2017.1398139. Epub 2017 Dec 5.
Pub MED

Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.NUEVO

Padmanabhan S, Burke RE.
Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27209. [Epub ahead of print] No abstract available.
Pub MED

Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.NUEVO

Hamadjida A, Nuara SG, Gourdon JC, Huot P.
J Neural Transm (Vienna). 2017 Dec 15. doi: 10.1007/s00702-017-1830-8. [Epub ahead of print]
Pub MED

One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.NUEVO

Iwaki H, Ando R, Miyaue N, Tada S, Tsujii T, Yabe H, Nishikawa N, Nagai M, Nomoto M.
J Neurol Sci. 2017 Dec 15;383:75-78. doi: 10.1016/j.jns.2017.10.030. Epub 2017 Oct 24.
Pub MED

Symptomatic, non-infectious, non-hemorrhagic edema after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease.NUEVO

Nazzaro JM, Pahwa R, Lyons KE.
J Neurol Sci. 2017 Dec 15;383:42-46. doi: 10.1016/j.jns.2017.10.003. Epub 2017 Oct 12.
Pub MED

Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.NUEVO

Miles A, Jardine M, Johnston F, de Lisle M, Friary P, Allen J.
J Neurol Sci. 2017 Dec 15;383:180-187. doi: 10.1016/j.jns.2017.11.015. Epub 2017 Nov 15.
Pub MED

Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease.NUEVO

Helmschrodt C, Höbel S, Schöniger S, Bauer A, Bonicelli J, Gringmuth M, Fietz SA, Aigner A, Richter A, Richter F.
Mol Ther Nucleic Acids. 2017 Dec 15;9:57-68. doi: 10.1016/j.omtn.2017.08.013. Epub 2017 Aug 30.
Pub MED

Altered effective connectivity contributes to micrographia in patients with Parkinson's disease and freezing of gait.NUEVO

Nackaerts E, Nieuwboer A, Broeder S, Swinnen S, Vandenberghe W, Heremans E.
J Neurol. 2017 Dec 14. doi: 10.1007/s00415-017-8709-3. [Epub ahead of print]
Pub MED

Expression of the DJ-1 protein in the serum of Chinese patients with Parkinson's disease.NUEVO

An C, Pu X, Xiao W, Zhang H.
Neurosci Lett. 2017 Dec 11;665:236-239. doi: 10.1016/j.neulet.2017.12.023. [Epub ahead of print]
Pub MED

Towards the identification of Idiopathic Parkinson's Disease from the speech. New articulatory kinetic biomarkers.NUEVO

Godino-Llorente JI, Shattuck-Hufnagel S, Choi JY, Moro-Velázquez L, Gómez-García JA.
PLoS One. 2017 Dec 14;12(12):e0189583. doi: 10.1371/journal.pone.0189583. eCollection 2017.
Pub MED

Modeling Parkinson's disease and treatment complications in rodents: potentials and pitfalls of the current options.NUEVO

Francardo V.
Behav Brain Res. 2017 Dec 10. pii: S0166-4328(17)31471-7. doi: 10.1016/j.bbr.2017.12.014. [Epub ahead of print] Review.
Pub MED

Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease.NUEVO

Milosevic L, Kalia SK, Hodaie M, Lozano AM, Fasano A, Popovic MR, Hutchison WD.
Brain. 2017 Dec 11. doi: 10.1093/brain/awx296. [Epub ahead of print]
Pub MED

[Social cognition in Parkinson's disease dementia and behavioral variant of frontotemporal dementia].NUEVO

Tabernero ME, Musich F, Cossini FC, Politis DG.
Rev Neurol. 2017 Dec 16;65(12):539-545. Spanish.
Pub MED

Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis.NUEVO

Mills KA, Greene MC, Dezube R, Goodson C, Karmarkar T, Pontone GM.
Int J Geriatr Psychiatry. 2017 Dec 13. doi: 10.1002/gps.4834. [Epub ahead of print]
Pub MED

CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.NUEVO

Nouhi M, Zhang X, Yao N, Chergui K.
CNS Neurosci Ther. 2017 Dec 11. doi: 10.1111/cns.12784. [Epub ahead of print]
Pub MED

The self-management balancing act of spousal care partners in the case of Parkinson's disease.NUEVO

Berger S, Chen T, Eldridge J, Thomas CA, Habermann B, Tickle-Degnen L.
Disabil Rehabil. 2017 Dec 12:1-9. doi: 10.1080/09638288.2017.1413427. [Epub ahead of print]
Pub MED

The Anthelmintic Drug Niclosamide and its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1.NUEVO

Barini E, Miccoli A, Tinarelli F, Mulholand K, Kadri H, Khanim F, Stojanovski L, Read KD, Burness K, Blow JJ, Mehellou Y, Muqit M.
Chembiochem. 2017 Dec 10. doi: 10.1002/cbic.201700500. [Epub ahead of print]
Pub MED

Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease.NUEVO

Bahdoudi S, Ghouili I, Hmiden M, do Rego JL, Lefranc B, Leprince J, Chuquet J, do Rego JC, Marcher AB, Mandrup S, Vaudry H, Tonon MC, Amri M, Masmoudi-Kouki O, Vaudry D.
Cell Mol Life Sci. 2017 Dec 20. doi: 10.1007/s00018-017-2727-2. [Epub ahead of print]
Pub MED

Can Dual Task Walking Improve in Parkinson's Disease After External Focus of Attention Exercise? A Single Blind Randomized Controlled Trial.NUEVO

Beck EN, Intzandt BN, Almeida QJ.
Neurorehabil Neural Repair. 2017 Dec 1:1545968317746782. doi: 10.1177/1545968317746782. [Epub ahead of print]
Pub MED

Differential Effects of Parkinson's Disease on Interneuron Subtypes within the Human Anterior Olfactory Nucleus.NUEVO

Ubeda-Bañon I, Flores-Cuadrado A, Saiz-Sanchez D, Martinez-Marcos A.
Front Neuroanat. 2017 Dec 5;11:113. doi: 10.3389/fnana.2017.00113. eCollection 2017.
Pub MED

Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease.NUEVO

Nido GS, Dölle C, Flønes I, Tuppen HA, Alves G, Tysnes OB, Haugarvoll K, Tzoulis C.
Neurobiol Aging. 2017 Dec 8;63:120-127. doi: 10.1016/j.neurobiolaging.2017.10.024. [Epub ahead of print]
Pub MED

Identification of crucial genes associated with Parkinson's disease using microarray data.NUEVO

Sun Y, Ye L, Zheng Y, Yang Z.
Mol Med Rep. 2017 Dec 18. doi: 10.3892/mmr.2017.8305. [Epub ahead of print]
Pub MED

Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients.NUEVO

Bartošová O, Bonnet C, Ulmanová O, Šíma M, Perlík F, Růžička E, Slanař O.
J Neural Transm (Vienna). 2017 Dec 19. doi: 10.1007/s00702-017-1829-1. [Epub ahead of print]
Pub MED

Biological and Clinical Implications of Comorbidities in Parkinson's Disease.NUEVO

Santiago JA, Bottero V, Potashkin JA.
Front Aging Neurosci. 2017 Dec 4;9:394. doi: 10.3389/fnagi.2017.00394. eCollection 2017. Review.
Pub MED

The Five Dimensions of Parkinson's Disease Genetic Risk.NUEVO

Coetzee GA, Pierce S.
J Parkinsons Dis. 2017 Dec 15. doi: 10.3233/JPD-171256. [Epub ahead of print]
Pub MED

Sleep-wake functions and quality of life in patients with subthalamic deep brain stimulation for Parkinson's disease.NUEVO

Bargiotas P, Eugster L, Oberholzer M, Debove I, Lachenmayer ML, Mathis J, Pollo C, Schüpbach WMM, Bassetti CL.
PLoS One. 2017 Dec 18;12(12):e0190027. doi: 10.1371/journal.pone.0190027. eCollection 2017.
Pub MED

[The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].NUEVO

Szász JA, Constantin V, Fazakas PA, Blényesi E, Grieb LG, Balla A, Sárig M, Szegedi K, Bartha EN, Szatmári S.
Orv Hetil. 2017 Dec;158(51):2023-2028. doi: 10.1556/650.2017.30914. Hungarian.
Pub MED

Dopaminergic polymorphisms associated with medication responsiveness of gait in Parkinson's disease.NUEVO

Miller NS, Chou KL, Bohnen NI, Müller MLTM, Seidler RD.
Parkinsonism Relat Disord. 2017 Dec 12. pii: S1353-8020(17)30836-2. doi: 10.1016/j.parkreldis.2017.12.010. [Epub ahead of print]
Pub MED

Identification of CHCHD10 variants in Chinese patients with Parkinson's disease.NUEVO

Zhou X, Liu Z, Guo J, Sun Q, Xu Q, Yan X, Tang B, Lei L.
Parkinsonism Relat Disord. 2017 Dec 8. pii: S1353-8020(17)30828-3. doi: 10.1016/j.parkreldis.2017.12.002. [Epub ahead of print] No abstract available.
Pub MED

The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.NUEVO

Valldeoriola F, Salvador A, Gómez-Arguelles JM, Marey J, Moya M, Ayuga Á, Ramírez F.
Int J Neurosci. 2017 Dec 17:1-7. doi: 10.1080/00207454.2017.1387111. [Epub ahead of print]
Pub MED

Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.NUEVO

Kessler C, Atasu B, Hanagasi H, Simón-Sánchez J, Hauser AK, Pak M, Bilgic B, Erginel-Unaltuna N, Gurvit H, Gasser T, Lohmann E.
Parkinsonism Relat Disord. 2017 Dec 9. pii: S1353-8020(17)30833-7. doi: 10.1016/j.parkreldis.2017.12.007. [Epub ahead of print]
Pub MED

The non-motor symptoms of Parkinson's disease of different motor types in early stage.NUEVO

Zhong LL, Song YQ, Cao H, Ju KJ, Yu L.
Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5745-5750. doi: 10.26355/eurrev_201712_14021.
Viendo del 121 al 160 de 321 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.